Black triangle for monitored EU drugs to kick in on 1 September
This article was originally published in SRA
Executive Summary
As of 1 September, the product information for all new EU drugs that are subjected to additional monitoring under the pharmacovigilance legislation will have to bear an inverted black triangle1.
You may also be interested in...
Black Triangle Scheme And Formal Inspections On the Cards In Australia
New pharmacovigilance-enhancing proposals from Australia’s Therapeutic Goods Administration signal the agency’s intention to become more proactive when it comes to monitoring drug sponsors.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.